SCHEMBL21595575

SCHEMBL21595575

[2H]C([2H])([2H])C([2H])([2H])Oc1ccc(C(=S)Nc2ccccc2F)nc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
NPC1 O15118 6/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
MAPT P10636 1/20 0.40
P4HTM Q9NXG6 1/20 0.39
HPGD P15428 1/20 0.38
RAB9A P51151 6/20 0.37
KMT2A Q03164 5/20 0.37
MEN1 O00255 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
CASP3 P42574 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30763078 1.00 ALDH1A1 (0.43) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL30763178 0.87 SMN1; SMN2 (0.55) ALDH1A1NPC1SMN1; SMN2P4HTMRAB9A
SCHEMBL21595511 0.87 SMN1; SMN2 (0.55) ALDH1A1NPC1SMN1; SMN2P4HTMRAB9A
SCHEMBL21595501 0.85 ALDH1A1 (0.56) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL30763008 0.85 ALDH1A1 (0.56) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL21595542 0.84 ALDH1A1 (0.43) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL30763109 0.82 SMN1; SMN2 (0.44) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL21595585 0.82 SMN1; SMN2 (0.44) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL21595584 0.78 KMT2A (0.45) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM
SCHEMBL30763060 0.78 KMT2A (0.45) ALDH1A1NPC1SMN1; SMN2MAPTP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR ALDH1A1 2191/4885NPC1 1998/4885SMN1; SMN2 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.